Previously CEO of EnteroBiotix, specialists in the development of microbiome modulating therapeutics, James has extensive c-suite level experience in the development and commercialisation of diagnostic and therapeutic products.
PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn's and ulcerative colitis (IBD).
Prior to EnteroBiotix James' roles included vice president of Clinical Laboratory Operations at Inivata, chief technology officer at Enterome, vice president of Research and Development at MDxHealth SA and chief operating officer at Response Genetics (IPO: NASDAQ).
This latest appointment to the PredictImmune senior team follows a wave of recent announcements including the start of a jointly sponsored study with the Crohn's and Colitis Foundation to validate PredictSURE IBD in the US market, and an announcement that PredictImmune has entered into an exclusive commercial partnership with KSL Biomedical to promote and provide PredictSURE IBD throughout North America.
Earlier in the year PredictImmune confirmed a strategic agreement with French diagnostic specialist, Theradiag, to commercialise PredictSURE IBD in France, Belgium, Luxembourg, Switzerland and the Maghreb countries.
This flurry of activity follows in the wake of the launch of PredictSURE IBD in the UK and Ireland in April this year.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007